Natera Announces First Quarter Earnings Conference Call | Natera
Back to releases

Natera Announces First Quarter Earnings Conference Call

SAN CARLOS, Calif., May 3, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2016 after the market close on May 10, 2016. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.

Conference Call Information:

Event: 

Natera's First Quarter Results Conference Call 

   

Date: 

Tuesday, May 10, 2016 

   

Time: 

1:30 p.m. PT (4:30 p.m. ET)

   

Live Dial-In: 

(877) 823-0171, Domestic 

   
 

(617) 500-6932, International

   

Conference ID: 

97911418

   

Webcast: 

investor.natera.com 

 

A webcast replay will be available at investor.natera.com.

About Natera

Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation.

Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit http://www.natera.com and connect on Twitter andFacebook.

Contacts:

Natera, Inc. 
Mike Brophy, Investor Relations, 650-249-9091 x1471 
mbrophy@natera.com

Natera, Inc. 
Laura Zobkiw, Corporate and Media Relations, 650-249-9091 x1649 
Lzobkiw@natera.com

SOURCE Natera, Inc.

Back to Top